In vivo evaluation of chitosan based local delivery system for atorvastatin in treatment of periodontitis


Ozdogan A. I. , Ilarslan Y. D. , KÖSEMEHMETOĞLU K., AKCA G. , KUTLU H. B. , Comerdov E., ...Daha Fazla

INTERNATIONAL JOURNAL OF PHARMACEUTICS, cilt.550, ss.470-476, 2018 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 550
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1016/j.ijpharm.2018.08.058
  • Dergi Adı: INTERNATIONAL JOURNAL OF PHARMACEUTICS
  • Sayfa Sayıları: ss.470-476

Özet

Periodontitis is a local inflammatory disease initiated by bacteria accumulation and results in cytokine mediated alveolar bone resorption and tissue destruction. In this study, the effect of locally delivered atorvastatin (2% w/v) containing chitosan formulations in the treatment of periodontitis was evaluated in rats with ligature induced periodontitis. The levels of interleukin-1beta (IL-1 beta), IL-6, IL-8, IL-10, transforming growth factor-beta 1 (TGF-beta 1), TGF-beta 2 and TGF-beta 3 were measured after treatment with formulations. Histomorphometric analysis included the measurements of the area of alveolar bone and the distance between cemento-enamel junction (CEJ) and connective tissue attachment to tooth. Inflammatory and osteoclastic activity scores were given semiquantitatively. Following the administration of atorvastatin, release of pro-inflammatory (IL-1 beta, IL-6 and IL-8) and anti-inflammatory (TGF-beta 1 and TGF-beta 2) cytokines was found to decrease, with a significant alveolar bone healing, when compared to that of control. The anti-inflammatory effect was observed to enhance in presence of chitosan. These findings suggest that chitosan based delivery system for a statin group drug, atorvastatin is a promising for the treatment of periodontal disease.